Nayara Rampazzo Morelli

Nayara Rampazzo Morelli

Auto-generated profile, based on publicly available information

Nayara Rampazzo Morelli

Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Research theme, Children's Hospital Research Institute of Manitoba

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
MMMichael Maes
Michael Maes
KBKamila Landucci Bonifacio
Kamila Landucci Bonifacio
HVHeber Odebrecht Vargas
Heber Odebrecht Vargas
SNSandra Odebrecht Vargas Nunes
Sandra Odebrecht Vargas Nunes
DBDécio Sabbatini Barbosa
Décio Sabbatini Barbosa

1 January 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
TBThiago Hissnauer Leal Baltus
Thiago Hissnauer Leal Baltus
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
CFCarine Coneglian de Farias
Carine Coneglian de Farias
KTKleber Paiva Trugilo
Kleber Paiva Trugilo
NONádia Calvo Martins Okuyama
Nádia Calvo Martins Okuyama
DBDécio Sabbatini Barbosa
Décio Sabbatini Barbosa

1 October 2024 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
CPCamille Préfontaine
Camille Préfontaine
JPJasmine Pipella
Jasmine Pipella
PTPeter Thompson
Peter Thompson
Beta cell senescence is an emerging contributor to the pathogenesis of type 1 diabetes, but candidate therapeutic targets have not been identified in human beta cells. In this study, we examined the role of a secreted factor, GDF15, and found that although it is not required to maintain viability during senescence, it is required to fine-tune gene expression programs involved in the senescence response during DNA damage in human beta cells.

2 February 2024 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
JPJasmine Pipella
Jasmine Pipella
PTPeter Thompson
Peter Thompson

13 November 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
CPCamille Préfontaine
Camille Préfontaine
JPJasmine Pipella
Jasmine Pipella
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
YCYi-Chun Chen
Yi-Chun Chen
CVC. Bruce Verchere
C. Bruce Verchere
PTPeter Thompson
Peter Thompson
Aims/hypothesis Residual pancreatic beta cells in type 1 diabetes show reduced insulin production but the mechanisms remain unclear. Beta cells undergo stress responses during type 1 diabetes, including endoplasmic reticulum (ER) stress and DNA damage-associated senescence, which may affect insulin production. ER stress reduces insulin production but whether senescence disrupts insulin production in human beta cells has not been investigated. Methods DNA damage-mediated senescence was induced using bleomycin in human donor islets. Relative levels of prohormone convertase 1/3 (PC1/3), prohormone convertase 2 (PC2), carboxypeptidase E (CPE) and the endogenous PC1/3 inhibitor, proprotein convertase subtilisin/kexin type 1 inhibitor (proSAAS), were quantified by western blot. Levels of proinsulin and insulin were measured by ELISA. Flow cytometry was used to measure insulin expression in islet cells. FACS was used to sort endogenous senescent beta cells from islets for analysis of insulin content. Proinsulin immunofluorescence staining was quantified in endogenous senescent vs non-senescent beta cells in pancreas tissue from control donors and donors with type 1 diabetes. Publicly available datasets were used to interrogate relationships between senescence effectors, proinsulin-processing genes and insulin content. DNA damage was induced with bleomycin in the non-proliferative female-fetus-derived EndoC-βH5 human beta cell model to study the impact of the DNA damage response on insulin production in clonal cells growth-arrested due to p16INK4A expression. Results DNA damage-mediated senescence led to increased PC1/3 without changes in levels of PC2, CPE or proSAAS in human islets. Consistent with these changes, no significant differences in proinsulin or insulin content were observed, compared with control islets. Flow cytometry confirmed maintenance of insulin content in DNA damage-mediated senescent beta cells vs control cells and sorted endogenous senescent beta cells had similar insulin content to non-senescent beta cells. Proinsulin staining was similar in endogenous senescent vs non-senescent beta cells from a control donor and donor with type 1 diabetes. Analysis of proteomics datasets from Humanislets.com and single-cell RNA-seq datasets from the Human Pancreas Analysis Program corroborated these findings. In EndoC-βH5 beta cells, which are growth-arrested, DNA damage led to decreased levels of CPE and proSAAS, and reduced levels of insulin. Conclusions/interpretation Our findings suggest that the expression of proinsulin-processing enzymes and the production of insulin are sustained in both chemically induced DNA damage-related senescence and in endogenous senescent adult human beta cells. Collectively, these findings suggest that senescent beta cells may be a source of insulin production among residual beta cells in type 1 diabetes. Graphical Abstract

10 July 2026 in Islets
Verified
Journal Article
Open access
RMRoozbeh Akbari Motlagh
Roozbeh Akbari Motlagh
NMNayara Rampazzo Morelli
Nayara Rampazzo Morelli
NANicole Alcasid
Nicole Alcasid
PTPeter Thompson
Peter Thompson
Type 1 diabetes (T1D) results from a chronic autoimmune disease leading to selective T-cell-mediated destruction of pancreatic β-cells and insulin deficiency. 1 While the role of immune system dysf...